OncLive TV

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses advances in the treatment of metastatic renal cell carcinoma.

Richard Carvajal, MD, director of Experimental Therapeutics and director of the Melanoma Service at Columbia University Medical Center, discusses the biology and distinctions of extracutaneous melanoma.

Alexandra Taylor, MD, consultant, clinical oncology, The Royal Marsden Hospital, discusses treatments in development for patients with endometrial cancer.

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the next steps following progression on checkpoint inhibitors in microsatellite instability-high (MSI-H) colorectal cancer (CRC).

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the combination of CTLA-4 and PD-1 inhibitors for the treatment of patients with multiple myeloma.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the evolution of adjuvant treatment for patients with HER2-positive breast cancer.

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing trials investigating treatment for patients with BRAF-mutant colorectal cancer (CRC).

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses a study of bb2121, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy.

Owen O'Connor, MD, PhD, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses acalabrutinib (Calquence) versus ibrutinib (Imbruvica) for the treatment of patients with mantle cell lymphoma

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the importance of clinical trials in the adjuvant setting of renal cell carcinoma.

Matthew S. Davids, MD, MMSc, associate director, Dana-Farber Cancer Institute, Center for Chronic Lymphocytic Leukemia, discusses the combination of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

Guru Sonpavde, MD, director of Bladder Cancer at the Dana-Farber Cancer Institute, discusses the potential for immunotherapy in penile cancer.

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses checkpoint inhibitors in liver cancer.

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses patient selection in the treatment of patients with ovarian cancer.

Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the importance of next-generation sequencing for patients with lung cancer.

Patrick Ott, MD, PhD, clinical director, Melanoma Center, Center for Immuno-Oncology, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses ipilimumab (Yervoy) and nivolumab (Opdivo) both in combination and as a monotherapy for patients with melanoma.

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the role of chimeric antigen receptor (CAR) T-cell therapy for pediatric patients with acute lymphocytic leukemia (ALL).

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the CheckMate-214 trial for patients with kidney cancer.

Umesh Mahantshetty, MD, MBBS, radiation oncologist, Tata Memorial Hospital, Mumbai, India, discusses unmet needs for patients with cervical cancer.

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the treatment options for patients with T790M-mutant lung cancer.

Key opinion leaders share the biggest advancements in oncology made this past year.

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses immunotherapy as a standard of care for patients with renal cell carcinoma (RCC).

Karen Reckamp, MD, MS, medical oncologist, City of Hope, discusses the role of molecular testing for patients with lung cancer.

Martee L. Hensley, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses Lynch syndrome for patients with endometrial cancer.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses androgen receptor (AR) inhibitors for patients with prostate cancer.

Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at City of Hope, discusses the mutational burden for patients with bladder cancer.

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses systemic treatment for patients with rare gynecologic tumors.

Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the role of checkpoint inhibitors and PARP inhibitors for patients with prostate cancer.

Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses the treatment of patients with stage III non-small cell lung cancer (NSCLC).

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of the clinical trial space for patients with kidney cancer.